Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma
about
Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma.Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer.The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 casesEBV in pediatric neoplasia--intensity of infection as independent prognostic factorPositivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma.Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinomaCurrent and emerging treatment options for nasopharyngeal carcinoma.Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation TherapyThe Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers.Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinomaSurvival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.Mitochondrial DNA haplogroup confers genetic susceptibility to nasopharyngeal carcinoma in Chaoshanese from Guangdong, China.Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes.Primary nasopharyngeal adenocarcinoma: a review.Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.Epstein-Barr virus DNA level as a novel prognostic factor in nasopharyngeal carcinoma: A meta-analysis.Cell-free Epstein-Barr virus-DNA in patients with nasopharyngeal carcinoma: Plasma versus urine.The C-reactive Protein/Albumin Ratio Is an independent Prognostic Factor for Overall Survival in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.An update on Epstein-Barr virus and nasopharyngeal carcinogenesis.Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.The predictive value of pre- and post-induction chemotherapy plasma EBV DNA level and tumor volume for the radiosensitivity of locally advanced nasopharyngeal carcinoma.Serologic and viral genome prevalence of HSV, EBV, and HCMV among healthy adults in Wuhan, China.Nasopharyngeal carcinoma: our experience.
P2860
Q33841441-10F362CC-9E62-4C99-A50B-F025866E4F3EQ34506005-A8432955-B726-4F63-853F-E3DBEE8BDFC3Q36073981-A25DE82D-96BB-4DFC-B554-014309145370Q36074308-0D1E7D72-32BF-45C4-97D0-B092BE6BDDA4Q36152889-369ACE2C-C1F3-45C0-892B-4744C00C7C01Q36299804-10959680-EB59-4BEB-8C29-1E305BA93C69Q36305182-9B63032A-FF79-4669-88EF-59A6D65CCDEEQ36335515-9B1B3F68-5113-4887-BAE1-45A47675F992Q36359374-E5E8E699-3C25-44F4-A4FE-751DA147D33DQ36628563-1544DECD-FF5F-42DC-B65F-497D3B821239Q36892139-09D1E3B5-F773-4DCB-9B5D-C91BFB2E63D9Q37081900-31E6D97B-D603-46CA-AA47-38F820E41565Q37269257-4BFB2BE5-A80D-4B5B-9170-807643A02BD8Q37539168-E97E54F4-69A1-44B9-88CF-F39A5ACBE245Q37719576-E4A574B6-88B3-4212-AC2A-B1796EAD8E93Q38004604-FBCFB7F6-96E0-4CD6-9962-F0C01E1BBDF8Q38888811-AD1C98E9-FC42-4430-8F7A-7E64D9326CF2Q38982843-4EF4B4F9-2042-4775-9957-FB7131C018E0Q41050251-9BD67BE8-B03B-44FC-A605-F87B8C508924Q42364956-5B9CE887-EA9B-4D61-AE77-1C2B41D5D213Q42935986-6E3EDBE1-B2A1-4080-BBD0-09055FB81F03Q45325137-E01271B3-666D-4A9E-8561-DB6D91D0142FQ45367926-68BFAE1F-D106-4C33-9DC8-0B741E2C836AQ47553783-76BB449F-3339-4AFF-A014-E8F3B9469F25Q47593207-F7E1D5E7-E8AA-4F38-AB9D-D8D66B773D64Q51680622-FF9E84B8-EBA5-4DD7-874F-B10BA3308ED9
P2860
Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma
description
im Januar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 18 September 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2007
@uk
name
Comparison of the prognostic i ...... ys in nasopharyngeal carcinoma
@en
Comparison of the prognostic i ...... ys in nasopharyngeal carcinoma
@nl
type
label
Comparison of the prognostic i ...... ys in nasopharyngeal carcinoma
@en
Comparison of the prognostic i ...... ys in nasopharyngeal carcinoma
@nl
prefLabel
Comparison of the prognostic i ...... ys in nasopharyngeal carcinoma
@en
Comparison of the prognostic i ...... ys in nasopharyngeal carcinoma
@nl
P2093
P1476
Comparison of the prognostic i ...... ys in nasopharyngeal carcinoma
@en
P2093
Chih-Wen Twu
Jeffrey Chao
Jian-Sheng Jan
Jin-Ching Lin
Wen-Miin Liang
Wen-Yi Wang
Ying-Tai Jin
P304
P356
10.1016/J.IJROBP.2006.07.012
P407
P577
2006-09-18T00:00:00Z